It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Intratumoral tertiary lymphoid structures (TLSs) have been associated with improved outcome in various cohorts of patients with cancer, reflecting their contribution to the development of tumor-targeting immunity. Here, we demonstrate that high-grade serous ovarian carcinoma (HGSOC) contains distinct immune aggregates with varying degrees of organization and maturation. Specifically, mature TLSs (mTLS) as forming only in 16% of HGSOCs with relatively elevated tumor mutational burden (TMB) are associated with an increased intratumoral density of CD8+ effector T (TEFF) cells and TIM3+PD1+, hence poorly immune checkpoint inhibitor (ICI)-sensitive, CD8+ T cells. Conversely, CD8+ T cells from immunologically hot tumors like non-small cell lung carcinoma (NSCLC) are enriched in ICI-responsive TCF1+ PD1+ T cells. Spatial B-cell profiling identifies patterns of in situ maturation and differentiation associated with mTLSs. Moreover, B-cell depletion promotes signs of a dysfunctional CD8+ T cell compartment among tumor-infiltrating lymphocytes from freshly isolated HGSOC and NSCLC biopsies. Taken together, our data demonstrate that – at odds with NSCLC – HGSOC is associated with a low density of follicular helper T cells and thus develops a limited number of mTLS that might be insufficient to preserve a ICI-sensitive TCF1+PD1+ CD8+ T cell phenotype. These findings point to key quantitative and qualitative differences between mTLSs in ICI-responsive vs ICI-irresponsive neoplasms that may guide the development of alternative immunotherapies for patients with HGSOC.
Intratumoral tertiary lymphoid structure (TLS) density has been associated with better prognosis in several cancer types. Here the authors provide a comprehensive characterization of TLSs in patients with high-grade serous ovarian carcinoma.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details












1 Sotio Biotech a.s., Prague, Czech Republic (GRID:grid.485032.8)
2 Sotio Biotech a.s., Prague, Czech Republic (GRID:grid.485032.8); 2nd Faculty of Medicine and University Hospital Motol, Department of Immunology, Charles University, Prague, Czech Republic (GRID:grid.412826.b) (ISNI:0000 0004 0611 0905)
3 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Department of Pathology, Prague, Czech Republic (GRID:grid.412819.7) (ISNI:0000 0004 0611 1895)
4 Faculty of Medicine and University Hospital Hradec Kralove, The Fingerland Department of Pathology, Charles University, Hradec Kralove, Czech Republic (GRID:grid.412539.8) (ISNI:0000 0004 0609 2284)
5 Charles University and General University Hospital, Department of Pathology, 1st Faculty of Medicine, Prague, Czech Republic (GRID:grid.411798.2) (ISNI:0000 0000 9100 9940)
6 Charles University, Department of Gynaecology, Obstetrics and Neonatology, General University Hospital in Prague, 1st Faculty of Medicine, Prague, Czech Republic (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X)
7 University Hospital Bulovka, Department of Gynecology and Obstetrics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X)
8 Charles University and University Hospital Motol, Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Prague, Czech Republic (GRID:grid.412826.b) (ISNI:0000 0004 0611 0905)
9 Institute of Microbiology of the Czech Academy of Sciences, Laboratory of Tumor Immunology, Prague, Czech Republic (GRID:grid.418800.5) (ISNI:0000 0004 0555 4846)
10 Institute of Molecular Genetics of the Czech Academy of Sciences, Czech Center for Phenogenomics, Vestec, Czech Republic (GRID:grid.418827.0) (ISNI:0000 0004 0620 870X)
11 Faculty of Medicine and University Hospital Hradec Kralove, Department of Gynecology and Obstetrics, Charles University, Hradec Kralove, Czech Republic (GRID:grid.412539.8) (ISNI:0000 0004 0609 2284)
12 University Hospital Hradec Kralove, Department of Pneumology, Hradec Kralove, Czech Republic (GRID:grid.412539.8) (ISNI:0000 0004 0609 2284)
13 Charles University, 3rd Faculty of Medicine and Thomayer University Hospital, Department of Thoracic Surgery, Prague, Czech Republic (GRID:grid.4491.8) (ISNI:0000 0004 1937 116X)
14 Cedars-Sinai Medical Center, Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, West Hollywood, USA (GRID:grid.50956.3f) (ISNI:0000 0001 2152 9905)
15 Charles University and University Hospital Motol, 3rd Department of Surgery, First Faculty of Medicine, Prague, Czech Republic (GRID:grid.412826.b) (ISNI:0000 0004 0611 0905)
16 Charles University and University Hospital Motol, Oncology and Pneumology Department, 2nd Faculty of Medicine, Prague, Czech Republic (GRID:grid.412826.b) (ISNI:0000 0004 0611 0905)
17 University Hospital Basel and University of Basel, Ovarian Cancer Research, Department of Biomedicine, Basel, Switzerland (GRID:grid.6612.3) (ISNI:0000 0004 1937 0642)
18 Imperial College London, Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
19 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Department of Gynecology and Obstetrics, Charles University, Prague, Czech Republic (GRID:grid.412819.7) (ISNI:0000 0004 0611 1895)
20 Los Angeles, Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
21 Weill Cornell Medical College, Department of Radiation Oncology, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); Sandra and Edward Meyer Cancer Center, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X); Caryl and Israel Englander Institute for Precision Medicine, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)